Adial pharmaceuticals announces completion of last patient, last visit in its onward™ phase 3 trial of ad04 for the treatment of patients with alcohol use disorder

Charlottesville, va., feb. 24, 2022 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the final patient has completed the last dose and last clinical visit in the company's ongoing onward™ phase 3 trial. onward is evaluating the efficacy, safety and tolerability of ad04 as a therapeutic agent for the treatment of alcohol use disorder (aud) in persons with certain target genotypes related to the serotonin transporter and receptor genes.
ADIL Ratings Summary
ADIL Quant Ranking